4//SEC Filing
Hohl Benjamin 4
Accession 0001415889-25-017532
CIK 0001672619other
Filed
Jun 16, 8:00 PM ET
Accepted
Jun 17, 4:24 PM ET
Size
9.2 KB
Accession
0001415889-25-017532
Insider Transaction Report
Form 4
Hohl Benjamin
CHIEF FINANCIAL OFFICER
Transactions
- Sale
Common Stock
2025-06-13$22.55/sh−3,000$67,655→ 23,000 total - Exercise/Conversion
Stock Option (right to buy)
2025-06-13−3,000→ 119,056 totalExercise: $2.48Exp: 2031-08-02→ Common Stock (3,000 underlying) - Exercise/Conversion
Common Stock
2025-06-13$2.48/sh+3,000$7,440→ 26,000 total
Footnotes (3)
- [F1]The option exercise and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 26, 2023.
- [F2]This transaction was executed in multiple trades at prices ranging from $22.50 to $22.56. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The option, originally for 262,120 shares, vested as to one-fourth of the shares on August 2, 2022, and the remainder of the shares vest in 36 equal monthly installments thereafter.
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001882764
Filing Metadata
- Form type
- 4
- Filed
- Jun 16, 8:00 PM ET
- Accepted
- Jun 17, 4:24 PM ET
- Size
- 9.2 KB